Results 281 to 290 of about 192,885 (309)

Pharmacotherapy of triple-negative breast cancer

Expert Opinion on Pharmacotherapy, 2009
The term 'triple-negative breast cancer' defines tumors that do not express estrogen receptors, progesterone receptors or Her2 on immunohistochemical analysis. This subgroup accounts for 15% of all types of breast cancer. Histologically, triple-negative breast cancers are poorly differentiated and are characterized by an aggressive clinical history.
Cagatay, Arslan, Omer, Dizdar, Kadri, Altundag   +2 more
openaire   +2 more sources

Immunotherapy in triple-negative breast cancer

Medical Oncology, 2017
Breast cancer can be classified based on the expression or lack of expression of protein receptors including estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth receptor 2 (Her2). The basal molecular subtype is mostly made up of breast cancers that do not express ER/PR or Her2, triple-negative breast cancers (TNBC) (Bertucci ...
Heather Katz, Mohamed Alsharedi
openaire   +2 more sources

Triple-negative breast cancers

Expert Review of Anticancer Therapy, 2023
Steven A, Narod, Rebecca, Dent
openaire   +2 more sources

Advanced Triple-Negative Breast Cancer

Seminars in Oncology Nursing
Our focus within this review is to summarize key advances and new therapeutic approaches within advanced triple-negative breast cancer. In addition, we highlight the importance of multidisciplinary management, discussing key issues for patients and importance of the supportive role that specialist nurses provide.Peer-reviewed literature, clinical ...
Grisma, Patel, Alison, Prince, Mark, Harries   +2 more
openaire   +2 more sources

Immunohistochemistry for Triple-Negative Breast Cancer

2016
Triple-negative breast cancers are a heterogeneous group of tumors that are, as yet, not entirely understood. Although triple-negative carcinomas are strictly defined as invasive carcinomas lacking expression of estrogen receptor, progesterone receptor, and HER2, some use the terms triple-negative and basal-like cancer synonymously.
Naidoo, Kalnisha, Pinder, Sarah E
openaire   +3 more sources

Dissecting the Heterogeneity of Triple-Negative Breast Cancer

Journal of Clinical Oncology, 2012
Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a heterogeneous disease, not only on the molecular level, but also on the pathologic and clinical levels. TNBC is associated with a significantly higher probability of relapse and poorer overall survival in the first few years after diagnosis when compared with other
O. Metzger Filho, A. Tutt, E. de Azambuja, K. S. Saini, G. Viale, S. Loi, I. Bradbury, J. M. Bliss, H. A. Jr Azim, P. Ellis, A. Di Leo, J. Baselga, C. Sotiriou, M. Piccart Gebhart   +13 more
openaire   +5 more sources

Pembrolizumab in Triple-Negative Breast Cancer

New England Journal of Medicine, 2022
Ryan, Sun, Lee-Jen, Wei
openaire   +3 more sources

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Özge Gümüsay, Damé Idossa   +2 more
exaly  

Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets

Cell Metabolism, 2021
Yue Gong, Yun-Song Yang, Tian-Jian Yu
exaly  

Disparities in triple negative breast cancer

Journal of the National Medical Association, 2023
Lisa, Newman, Edith, Mitchell
openaire   +2 more sources